Michele Thai1, Emily Reeve2,3,4, Sarah N Hilmer2,3, Katie Qi1, Sallie-Anne Pearson1,5,4, Danijela Gnjidic6,7. 1. Faculty of Pharmacy, The University of Sydney, Pharmacy and Bank Building A15, Sydney, NSW, 2006, Australia. 2. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. 3. Kolling Institute of Medical Research, Royal North Shore Hospital, Level 12 Kolling Building, St Leonards, NSW, 2065, Australia. 4. Centre for Big Data Research in Health, UNSW Australia, Level 1, AGSM Building (G27), Sydney, NSW, 2052, Australia. 5. School of Public Health, The University of Sydney, Sydney, NSW, Australia. 6. Faculty of Pharmacy, The University of Sydney, Pharmacy and Bank Building A15, Sydney, NSW, 2006, Australia. danijela.gnjidic@sydney.edu.au. 7. Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. danijela.gnjidic@sydney.edu.au.
Abstract
PURPOSE: Statins are among the most frequently prescribed medications internationally. Older people are commonly prescribed multiple medications and are at an increased risk of drug-drug interactions, including statin-drug interactions. The aim of this study was to conduct a systematic review of current evidence on the prevalence of statin-drug interactions in older people. METHODS: A systematic search of observational studies in Embase, Medline, and PubMed was conducted. Articles were included if they were published in English during the period July 2000-July 2014 and reported on the prevalence of statin-drug interactions in people over 65 years of age. Two reviewers independently assessed the articles for eligibility and extracted the data. RESULTS: The search returned 1556 eligible articles. A total of 19 articles met the inclusion criteria. In studies (n = 7) that focused on statin users only, the prevalence of potential statin-drug interactions assessed using different measures ranged from 0.19 to 33.0 %. In studies that examined drug interactions across a population of both statin users and non-users (n = 12), the prevalence of potential statin-drug interactions ranged from 0.1 to 7.1 % (n = 8), and the prevalence of clinically relevant statin-drug interactions ranged from 1.5 to 4 % (n = 4). CONCLUSIONS: Current published evidence suggests substantial variations in the prevalence of statin-drug interactions and their clinical relevance. Further studies are necessary to provide a better understanding of the prevalence of clinically significant statin-drug interactions, the medications most frequently contributing to statin-drug interactions, and impact on relevant clinical outcomes in older people.
PURPOSE: Statins are among the most frequently prescribed medications internationally. Older people are commonly prescribed multiple medications and are at an increased risk of drug-drug interactions, including statin-drug interactions. The aim of this study was to conduct a systematic review of current evidence on the prevalence of statin-drug interactions in older people. METHODS: A systematic search of observational studies in Embase, Medline, and PubMed was conducted. Articles were included if they were published in English during the period July 2000-July 2014 and reported on the prevalence of statin-drug interactions in people over 65 years of age. Two reviewers independently assessed the articles for eligibility and extracted the data. RESULTS: The search returned 1556 eligible articles. A total of 19 articles met the inclusion criteria. In studies (n = 7) that focused on statin users only, the prevalence of potential statin-drug interactions assessed using different measures ranged from 0.19 to 33.0 %. In studies that examined drug interactions across a population of both statin users and non-users (n = 12), the prevalence of potential statin-drug interactions ranged from 0.1 to 7.1 % (n = 8), and the prevalence of clinically relevant statin-drug interactions ranged from 1.5 to 4 % (n = 4). CONCLUSIONS: Current published evidence suggests substantial variations in the prevalence of statin-drug interactions and their clinical relevance. Further studies are necessary to provide a better understanding of the prevalence of clinically significant statin-drug interactions, the medications most frequently contributing to statin-drug interactions, and impact on relevant clinical outcomes in older people.
Authors: Tessa K Morgan; Margaret Williamson; Marie Pirotta; Kay Stewart; Stephen P Myers; Joanne Barnes Journal: Med J Aust Date: 2012-01-16 Impact factor: 7.738
Authors: Dima M Qato; G Caleb Alexander; Rena M Conti; Michael Johnson; Phil Schumm; Stacy Tessler Lindau Journal: JAMA Date: 2008-12-24 Impact factor: 56.272
Authors: Rafel Ramos; Marc Comas-Cufí; Ruth Martí-Lluch; Elisabeth Balló; Anna Ponjoan; Lia Alves-Cabratosa; Jordi Blanch; Jaume Marrugat; Roberto Elosua; María Grau; Marc Elosua-Bayes; Luis García-Ortiz; Maria Garcia-Gil Journal: BMJ Date: 2018-09-05